BIOGY:OTC-BioGaia AB (publ) (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC

Last Closing Price

USD 27.75

Change

0.00 (0.00)%

Market Cap

USD 0.80B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BioGaia AB (publ) (BIOGY) Stock Analysis:
Based on the BioGaia AB (publ) stock forecasts from 0 analysts, the average analyst target price for BioGaia AB (publ) is not available over the next 12 months. BioGaia AB (publ)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioGaia AB (publ) is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, BioGaia AB (publ)’s stock price was USD 27.75. BioGaia AB (publ)’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -11.11% over the last year.

No recent analyst target price found for BioGaia AB (publ)
No recent average analyst rating found for BioGaia AB (publ)

About

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures t ...Read More

Employees : 144

Currency: USD

Country : USA

Technical Indicators

Beta : -0.59

52 Week High : 24.00

52 Week Low : 24.00

200 Day Moving Average : 24.00

50 Day Moving Average : 24.00

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHCCF Benchmark Holdings plc

N/A

 USD0.33B 75.60 -12.10
LJUIF SSY Group Limited

N/A

 USD-1,669,326,336.00 26.57 12.23

ETFs Containing BIOGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers - Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -11.11% 50% F 44% F
Dividend Return 0.65% 50% F 6% F
Total Return -10.47% 50% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.72% 100% A+ 40% F
Dividend Return -0.15% 50% F 4% F
Total Return 6.57% 100% A+ 37% F
Risk Return Profile  
Volatility (Standard Deviation) 17.47% 67% D+ 85% B
Risk Adjusted Return 37.60% 100% A+ 59% F
Market Capitalization 0.80B 100% A+ 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers - Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.20 67% D+ 19% F
Price/Book Ratio 1.68 67% D+ 50% F
Price / Cash Flow Ratio 30.15 33% F 7% F
EV/EBITDA -264.23 100% A+ 99% A+
Management Effectiveness  
Return on Equity 39.37% 100% A+ 95% A
Return on Invested Capital 42.61% 100% A+ 90% A-
Return on Assets 24.90% 100% A+ 99% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.59 100% A+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.